Literature DB >> 9099263

Osteopontin is associated with bioprosthetic heart valve calcification in humans.

M Shen1, P Marie, D Farge, S Carpentier, C De Pollak, M Hott, L Chen, B Martinet, A Carpentier.   

Abstract

Calcification of non-osseous tissues such as heart valves or vessels is a major concern in clinical practice. The exact mechanism is still unknown. Numerous studies have shown that mineral deposits of crystalline hydroxyapatite within these tissues were associated with increased non-collagenous protein content. More recently osteopontin was found to be associated with calcification in living tissues such as vessels and native human aortic valves. The aim of this study was to determine whether or not non-collagenous proteins can also be found in non-living tissues such as glutaraldehyde-pretreated porcine valves after implantation in humans. Thirty-eight glutaraldehyde pretreated porcine bioprostheses were studied: 16 not implanted and 22 after 11 years of implantation in the aortic and mitral valve position in humans. In areas of calcification vizualized by Von Kossa staining and microradiography, immunostaining using polyclonal antibodies against calcium-binding proteins showed osteopontin positive staining and no staining for osteocalcin, bone sialoprotein or osteonectin. In uncalcified areas and in non-implanted values, staining for osteopontin or other calcium-binding proteins was negative. Western blot analysis of macroscopically calcified and uncalcified areas showed that several proteins were adsorbed in implanted values and confirmed the presence of osteopontin in the calcified areas, while no immunolabelling was found in non-calcified areas, in uncalcified valves and in non-implanted valves. Thus the presence of osteopontin in the calcified areas of bioprosthetic heart valves implanted in human indicates that this protein is associated with bioprosthetic valvular calcification. Since these values are made of non-living connective tissue, and no cell immunostained for osteopontin was found around the calcified area, this suggests that a non-cellular mediated mechanism involving protein adsorption may play a role in bioprosthetic valvular calcification.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099263     DOI: 10.1016/s0764-4469(99)80086-9

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  14 in total

1.  Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.

Authors:  Susan A Steitz; Mei Y Speer; Marc D McKee; Lucy Liaw; Manuela Almeida; Hsueh Yang; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis.

Authors:  Lauren M Pachman; Adele L Boskey
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

3.  Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease.

Authors:  Rachana Sainger; Juan B Grau; Paolo Poggio; Emanuela Branchetti; Joseph E Bavaria; Joseph H Gorman; Robert C Gorman; Giovanni Ferrari
Journal:  Biomarkers       Date:  2011-12-23       Impact factor: 2.658

4.  Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease.

Authors:  Juan B Grau; Paolo Poggio; Rachana Sainger; William J Vernick; William F Seefried; Emanuela Branchetti; Benjamin C Field; Joseph E Bavaria; Michael A Acker; Giovanni Ferrari
Journal:  Ann Thorac Surg       Date:  2011-11-16       Impact factor: 4.330

Review 5.  Selection of artificial valve for the patients on hemodialysis.

Authors:  Hirofumi Takemura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-12-07

6.  Role of carbonic anhydrase II in ectopic calcification.

Authors:  Rupak M Rajachar; Elyse Tung; Anh Q Truong; Amy Look; Cecilia M Giachelli
Journal:  Cardiovasc Pathol       Date:  2008-03-05       Impact factor: 2.185

7.  Bioprosthetic valve degeneration due to cholesterol deposition in a patient with normal lipid profile.

Authors:  Leslie Price; Allan Sniderman; Attila Omerglu; Kevin Lachapelle
Journal:  Can J Cardiol       Date:  2007-03-01       Impact factor: 5.223

8.  Renal papillary calcification and the development of calcium oxalate monohydrate papillary renal calculi: a case series study.

Authors:  Fèlix Grases; Antonia Costa-Bauzá; Rafel M Prieto; Antonio Conte; Antonio Servera
Journal:  BMC Urol       Date:  2013-03-11       Impact factor: 2.264

9.  Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo.

Authors:  Mei Y Speer; Marc D McKee; Robert E Guldberg; Lucy Liaw; Hsueh-Ying Yang; Elyse Tung; Gerard Karsenty; Cecilia M Giachelli
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

10.  Osteopontin is elevated in patients with mitral annulus calcification independent from classic cardiovascular risk factors.

Authors:  Michael Sponder; Christian Reuter; Monika Fritzer-Szekeres; Brigitte Litschauer; Thomas Binder; Jeanette Strametz-Juranek
Journal:  BMC Cardiovasc Disord       Date:  2016-06-10       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.